from
TF Market Research31 page report
published Aug 29, 2006
Price
$1,200.00 available for immediate download
This report is also available for purchase on a
per-page basis.
Report Overview
Purchase by Section
Search Inside
About
TF Market Research
...Valentis, Inc., a biotechnology company, focuses on the creation of cardiovascular therapeutics and associated delivery systems. It develops products for peripheral arterial disease. Peripheral arterial disease is a vascular occlusive disease of the lower extremities. The company has developed a series of technologies, including gene delivery and expression technologies, and proprietary formulation and manufacturing technologies that enable the generation of therapeutics to treat a range of diseases. Its primary products include VLTS ###, a Phase IIb testing anti -inflammatory drug; DEL -#, an angiogenic protein that promotes the formation of new blood vessels; and Deltavasc, which is a Phase IIa clinical trial completed investigational product that incorporates the DEL -# gene to stimulate new blood vessel growth. The company also has ## products in development by licensors of Valentis various technologies to treat infectious diseases and cancer. In addition, it offers contract...
|
| Source: | LIFE SCIENCE ANALYTICS
|
| Company: | VALENTIS INC.
|
| Geographic Regions: | CALIFORNIA (STATE OF), NORTH AMERICA, PACIFIC STATES REGION, UNITED STATES OF AMERICA
|
| Non-Billable Page Numbers: | 31
|
| Format: | | PDF |  |
|
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
